Comparison Study of High Frequency Percussive Ventilation With Conventional Ventilation
| Status: | Withdrawn |
|---|---|
| Conditions: | Pneumonia, Hospital, Pulmonary |
| Therapuetic Areas: | Pulmonary / Respiratory Diseases, Other |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 1/19/2019 |
| Start Date: | January 2006 |
| End Date: | December 31, 2009 |
A Prospective Randomized Controlled Trial Comparing High Frequency Percussive Ventilation With Conventional Mechanical Ventilation Utilizing Protective Lung Strategies in Patients With Acute Lung Injury/Acute Respiratory Distress Syndrome
This study is designed to exam the effects of early management with high frequency percussive
ventilation (HFPV) on patients with lung injury. Patients at risk for Acute Respiratory
Distress Syndrome (ARDS) will be enrolled and randomized to one of two groups. One group will
be managed with HFPV. The second group will be managed with conventional ventilation
utilizing lung protective techniques. The primary endpoint of the study is rate of ventilator
associated pneumonia. We hypothesized that use of HFPV in patients at risk for the
development of ARDS will decrease the rate of ventilator associated pneumonia when compared
to patients managed with conventional ventilation.
ventilation (HFPV) on patients with lung injury. Patients at risk for Acute Respiratory
Distress Syndrome (ARDS) will be enrolled and randomized to one of two groups. One group will
be managed with HFPV. The second group will be managed with conventional ventilation
utilizing lung protective techniques. The primary endpoint of the study is rate of ventilator
associated pneumonia. We hypothesized that use of HFPV in patients at risk for the
development of ARDS will decrease the rate of ventilator associated pneumonia when compared
to patients managed with conventional ventilation.
Specific Aim 1: This prospective randomized trial will enroll 180 patients with ALI/ARDS over
a forty-eight month period. One cohort will receive conventional mechanical ventilation
adhering to our well defined protocol of protective lung strategies. A second cohort will
have these same strategies applied utilizing the VDR/HFPV. Out come measures will include;
ICU/Hospital length of stay, pulmonary infectious complications, airway pressure related
complications, PaO2/PaCO2 levels, hemodynamic profiles, and ventilators days.
We hypothesize that patients with Acute Lung Injury (ALI )and/or Acute Respiratory Distress
Syndrome (ARDS) managed primarily with HFPV will have fewer ventilators days, fewer
infectious complications, and shorter ICU/hospital lengths of stay than patients managed with
conventional mechanical ventilation techniques, while maintaining similar oxygenation (PaO2),
ventilation (PaCO2), metabolic (pH), and hemodynamic (cardiac output) parameters.
ARDS and ALI have been shown to cause elevations in circulating inflammatory mediators as
well as local (alveolar) mediators. The presence of increased amounts of both circulating and
alveolar cytokines (inflammatory mediators) has been associated with increased mortality in
patients with ARDS/ALI. The pulmonary capillary bed is a rich source of these inflammatory
cytokines and the effects of ventilator strategies on circulating and compartmentalized
(alveolar) cytokine levels may affect outcome.
Specific Aim 2: Circulating and alveolar inflammatory mediators (IL-6, IL-1-beta, IL-10, and
TNF-alpha) will be measured, and activation of other markers of increased synthesis of
inflammatory mediators (NF-kappa B and p38 map kinase) will be determined in isolated
peripheral blood and alveolar leukocytes.
We hypothesize that patients with ALI/ARDS managed with HFPV will have lower levels of
circulating and alveolar pro-inflammatory cytokines (IL-6, IL-1-beta and TNF-alpha) as well
as less activation of NF-kappa B and p38 MAP kinase from peripheral blood and alveolar
leukocytes.
a forty-eight month period. One cohort will receive conventional mechanical ventilation
adhering to our well defined protocol of protective lung strategies. A second cohort will
have these same strategies applied utilizing the VDR/HFPV. Out come measures will include;
ICU/Hospital length of stay, pulmonary infectious complications, airway pressure related
complications, PaO2/PaCO2 levels, hemodynamic profiles, and ventilators days.
We hypothesize that patients with Acute Lung Injury (ALI )and/or Acute Respiratory Distress
Syndrome (ARDS) managed primarily with HFPV will have fewer ventilators days, fewer
infectious complications, and shorter ICU/hospital lengths of stay than patients managed with
conventional mechanical ventilation techniques, while maintaining similar oxygenation (PaO2),
ventilation (PaCO2), metabolic (pH), and hemodynamic (cardiac output) parameters.
ARDS and ALI have been shown to cause elevations in circulating inflammatory mediators as
well as local (alveolar) mediators. The presence of increased amounts of both circulating and
alveolar cytokines (inflammatory mediators) has been associated with increased mortality in
patients with ARDS/ALI. The pulmonary capillary bed is a rich source of these inflammatory
cytokines and the effects of ventilator strategies on circulating and compartmentalized
(alveolar) cytokine levels may affect outcome.
Specific Aim 2: Circulating and alveolar inflammatory mediators (IL-6, IL-1-beta, IL-10, and
TNF-alpha) will be measured, and activation of other markers of increased synthesis of
inflammatory mediators (NF-kappa B and p38 map kinase) will be determined in isolated
peripheral blood and alveolar leukocytes.
We hypothesize that patients with ALI/ARDS managed with HFPV will have lower levels of
circulating and alveolar pro-inflammatory cytokines (IL-6, IL-1-beta and TNF-alpha) as well
as less activation of NF-kappa B and p38 MAP kinase from peripheral blood and alveolar
leukocytes.
Inclusion Criteria:
- PaO2/FiO2 < 300 for less than 24 hours (Ratio of Partial pressure of oxygen to
Fraction of inspired oxygen)
Exclusion Criteria:
- Documented Pneumonia,
- Documented Congestive Heart Failure,
- Immunosuppression,
- Enrolled in other interventional trial,
We found this trial at
1
site
Click here to add this to my saved trials
